デフォルト表紙
市場調査レポート
商品コード
914038

世界の肝炎治療薬市場:規模、シェア、見通し、機会分析

Global Hepatitis Drugs Market, By Drug Class, By Disease Type, By Route of Administration, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2019-2027

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 173 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.84円
世界の肝炎治療薬市場:規模、シェア、見通し、機会分析
出版日: 2019年08月19日
発行: Coherent Market Insights
ページ情報: 英文 173 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートは世界の肝炎治療薬市場について調査しており、市場機会や動向、成長および阻害要因、薬剤クラス・疾患タイプ・投与経路・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 調査の目的および前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場の概要

  • レポートの説明
  • エグゼクティブサマリー
  • Coherent Opportunity Map (COM)

第3章 市場力学、規制、動向分析

  • 市場力学
  • 影響分析
  • 市場動向
  • 主な開発
  • 規制の状況
  • 疫学分析
  • 償還シナリオ
  • PEST分析

第4章 市場分析:薬剤クラス別

  • イントロダクション
  • インターフェロンアルファ
  • HIV NRTI
  • ヌクレオチドポリメラーゼ/ NS5A阻害剤の組み合わせ
  • C型肝炎プロテアーゼ/ NS5A阻害剤の組み合わせ
  • NS5A阻害剤
  • ヌクレオチドポリメラーゼ阻害剤
  • ヌクレオシドアナログ抗ウイルス薬
  • 血栓形成促進剤

第5章 市場分析:病気のタイプ別

  • イントロダクション
  • B型肝炎
  • C型肝炎
  • その他

第6章 市場分析:管理経路別

  • イントロダクション
  • 経口
  • 注射

第7章 市場分析:流通経路別

  • イントロダクション
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第8章 市場分析:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • アフリカ
  • 中東

第9章 競合情勢

  • 企業プロファイル
    • Merck & Co. Inc.
    • Gilead Sciences Inc.
    • AbbVie Inc.
    • Bristol Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • LAURUS Labs
    • Zydus Cadila
    • Hetero Healthcare Limited
    • GlaxoSmithKline PLC.
    • Cipla Inc.
  • アナリストビュー

第10章 セクション

  • 参照資料
  • 調査方法
  • 当社について
目次

Hepatitis refers to an inflammatory condition of the liver. Viral infections of the liver classified as hepatitis include hepatitis A, B, C, D, and E. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are most likely to become ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women which increase maternal and fetal mortality and morbidity.

Market Dynamics

Increasing prevalence of hepatitis worldwide is expected to boost growth of the hepatitis drugs market. According to World Health Organization (WHO), in 2015, 257 million people were living with chronic hepatitis B infection, and in 2016, while 4.5 million (16.7%) of the people were diagnosed with hepatitis B . Hepatitis B can be prevented by safe and effective vaccines. Additionally, the WHO aims for eliminating viral hepatitis infections which include 90% reduction of new infections, 65% reduction in deaths resulting from viral hepatitis infections worldwide by 2030.

However, factors such as longer development and approval time for hepatitis drugs is expected to hinder growth of the hepatitis drugs market during the forecast period. For instance, according to the National Center for Biotechnology Information 2017, the development of a new medicine for hepatitis from target identification through approval for marketing, takes 12 years or longer.

Key features of the study:

  • This report provides in-depth analysis of the hepatitis drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2019 - 2027, considering 2018 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global hepatitis drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global hepatitis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for hepatitis drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

  • Global Hepatitis Drugs Market, By Drug Class:
    • Interferon Alphas
    • HIV NRTIs
    • Nucleotide Polymerase / NS5A Inhibitor Combinations
    • Hepatitis C Protease / NS5A Inhibitor Combinations
    • NS5A Inhibitors
    • Nucleotide Polymerase Inhibitors
    • Nucleoside Analogue Antivirals
    • Thrombopoiesis Stimulating Agents
  • Global Hepatitis Drugs Market, By Disease Type:
    • Hepatitis B
    • Hepatitis C
    • Others
  • Global Hepatitis Drugs Market, By Route of Administration:
    • Oral
    • Injection
  • Global Hepatitis Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Hepatitis Drugs Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Drug Class:
    • Interferon Alphas
    • HIV NRTIs
    • Nucleotide Polymerase / NS5A Inhibitor Combinations
    • Hepatitis C Protease / NS5A Inhibitor Combinations
    • NS5A Inhibitors
    • Nucleotide Polymerase Inhibitors
    • Nucleoside Analogue Antivirals
    • Thrombopoiesis Stimulating Agents
      • By Disease Type:
    • Hepatitis B
    • Hepatitis C
    • Others
      • By Route of Administration:
    • Oral
    • Injection
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Drug Class:
    • Interferon Alphas
    • HIV NRTIs
    • Hepatitis B NRTIs
    • Nucleotide Polymerase / NS5A Inhibitor Combinations
    • Hepatitis C Protease / NS5A Inhibitor Combinations
    • NS5A Inhibitors
    • Nucleotide Polymerase Inhibitors
    • Nucleoside Analogue Antivirals
    • Thrombopoiesis Stimulating Agents
      • By Disease Type:
    • Hepatitis B
    • Hepatitis C
    • Others
      • By Route of Administration:
    • Oral
    • Injection
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Drug Class:
    • Interferon Alphas
    • HIV NRTIs
    • Nucleotide Polymerase / NS5A Inhibitor Combinations
    • Hepatitis C Protease / NS5A Inhibitor Combinations
    • NS5A Inhibitors
    • Nucleotide Polymerase Inhibitors
    • Nucleoside Analogue Antivirals
    • Thrombopoiesis Stimulating Agents
      • By Disease Type:
    • Hepatitis B
    • Hepatitis C
    • Others
      • By Route of Administration:
    • Oral
    • Injection
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Drug Class:
    • Interferon Alphas
    • HIV NRTIs
    • Nucleotide Polymerase / NS5A Inhibitor Combinations
    • Hepatitis C Protease / NS5A Inhibitor Combinations
    • NS5A Inhibitors
    • Nucleotide Polymerase Inhibitors
    • Nucleoside Analogue Antivirals
    • Thrombopoiesis Stimulating Agents
      • By Disease Type:
    • Hepatitis B
    • Hepatitis C
    • Others
      • By Route of Administration:
    • Oral
    • Injection
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Drug Class:
    • Interferon Alphas
    • HIV NRTIs
    • Nucleotide Polymerase / NS5A Inhibitor Combinations
    • Hepatitis C Protease / NS5A Inhibitor Combinations
    • NS5A Inhibitors
    • Nucleotide Polymerase Inhibitors
    • Nucleoside Analogue Antivirals
    • Thrombopoiesis Stimulating Agents
      • By Disease Type:
    • Hepatitis B
    • Hepatitis C
    • Others
      • By Route of Administration:
    • Oral
    • Injection
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Africa
      • By Country:
    • South Africa
    • Central Africa
    • North Africa
      • By Drug Class:
    • Interferon Alphas
    • HIV NRTIs
    • Nucleotide Polymerase / NS5A Inhibitor Combinations
    • Hepatitis C Protease / NS5A Inhibitor Combinations
    • NS5A Inhibitors
    • Nucleotide Polymerase Inhibitors
    • Nucleoside Analogue Antivirals
    • Thrombopoiesis Stimulating Agents
      • By Disease Type:
    • Hepatitis B
    • Hepatitis C
    • Others
      • By Route of Administration:
    • Oral
    • Injection
      • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
    • Merck & Co. Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Gilead Sciences Inc.
    • AbbVie Inc.
    • Bristol Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • LAURUS Labs
    • Zydus Cadila
    • Hetero Healthcare Limited
    • GlaxoSmithKline PLC
    • Cipla Inc.

"*" marked represents similar segmentation in other categories in the respective section

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Disease Type
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Landscape
  • Epidemiology Analysis
  • Reimbursement Scenario
  • PEST Analysis

4. Global Hepatitis Drugs Market, By Drug Class, 2019 - 2027 (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Interferon Alphas
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Million)
  • HIV NRTIs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Million)
  • Nucleotide Polymerase / NS5A Inhibitor Combinations
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Million)
  • Hepatitis C Protease / NS5A Inhibitor Combinations
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Million)
  • NS5A Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Million)
  • Nucleotide Polymerase Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Million)
  • Nucleoside Analogue Antivirals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Million)
  • Thrombopoiesis Stimulating Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Million)

5. Global Hepatitis Drugs Market, By Disease Type, 2019 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hepatitis B
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Million)
  • Hepatitis C
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Million)

6. Global Hepatitis Drugs Market, By Route of Administration, 2019 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Million)
  • Injection
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Million)

7. Global Hepatitis Drugs Market, By Distribution Channel, 2019 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2019 - 2027, (US$ Million)

8. Global Hepatitis Drugs Market, By Region, 2019 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2019 and 2027 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2027
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Class, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Type, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2019 - 2027, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Class, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Type, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2019 - 2027, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Type, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2019 - 2027, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Class, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Type, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2019 - 2027, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Class, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Type, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2019 - 2027, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drug Class, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Disease Type, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Route of Administration, 2019 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2019 - 2027, (US$ Million)l
    • Market Size and Forecast, By Country, 2019 - 2027, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East

9. Competitive Landscape

  • Company Profiles
    • Merck & Co. Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Gilead Sciences Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • AbbVie Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Bristol Myers Squibb Company
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • F. Hoffmann-La Roche Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • LAURUS Labs
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Zydus Cadila
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Hetero Healthcare Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • GlaxoSmithKline PLC.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Cipla Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About Us and Sales Contact